- Current report filing (8-K)
January 08 2010 - 5:09PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
__________________
FORM
8-K
__________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event
reported): January
8, 2010
Lexicon
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
000-30111
|
76-0474169
|
(State
or other jurisdiction of
incorporation
or organization)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification
Number)
|
8800
Technology Forest Place
The
Woodlands, Texas 77381
(Address
of principal executive
offices
and Zip Code)
(281)
863-3000
(Registrant’s
telephone number,
including
area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligations of the registrant under any of the following
provisions:
|
□
|
Written
communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
|
□
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
□
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
|
|
□
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
|
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain
Officers
|
(b) On
January 8, 2010, Ajay Bansal left his position as our executive vice president,
corporate development and chief financial officer. In such capacity, Mr. Bansal
had performed the functions of our principal financial officer.
(c) On
January 8, 2010, James F. Tessmer assumed the function of our principal
financial officer. Mr. Tessmer, who had previously served in that
function before Mr. Bansal’s appointment, will also continue in his present
function as our principal accounting officer. Mr. Tessmer, 50, has
been our vice president, finance and accounting since November 2007 and
previously served as our senior director of finance from February 2004 to
November 2007 and director of finance from April 2001 to February
2004. Mr. Tessmer is a certified public accountant and received his
B.B.A. from the University of Wisconsin – Milwaukee and his M.B.A. from the
University of Houston.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Lexicon
Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
Date: January
8, 2010
|
By:
|
/s/
Jeffrey L.
Wade
|
|
|
Jeffrey
L. Wade
|
|
|
Executive Vice
President
and
|
|
|
General
Counsel
|
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jul 2023 to Jul 2024